Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108709857> ?p ?o ?g. }
- W2108709857 endingPage "2164" @default.
- W2108709857 startingPage "2158" @default.
- W2108709857 abstract "No AccessJournal of UrologyAdult Urology1 Dec 2012Transcript Levels of Androgen Receptor Variant AR-V1 or AR-V7 Do Not Predict Recurrence in Patients with Prostate Cancer at Indeterminate Risk for Progression Hongjuan Zhao, Marc A. Coram, Rosalie Nolley, Stephen W. Reese, Sarah R. Young, and Donna M. Peehl Hongjuan ZhaoHongjuan Zhao More articles by this author , Marc A. CoramMarc A. Coram More articles by this author , Rosalie NolleyRosalie Nolley More articles by this author , Stephen W. ReeseStephen W. Reese More articles by this author , Sarah R. YoungSarah R. Young More articles by this author , and Donna M. PeehlDonna M. Peehl More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.08.014AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: AR-V7, a ligand independent splice variant of androgen receptor, may support the growth of castration resistant prostate cancer and have prognostic value. Another variant, AR-V1, interferes with AR-V7 activity. We investigated whether AR-V7 or V1 expression would predict biochemical recurrence in men at indeterminate (about 50%) risk for progression following radical prostatectomy. Materials and Methods: AR-V7 and V1 transcripts in a mixed grade cohort of 53 men in whom cancer contained 30% to 70% Gleason grade 4/5 and in a grade 3 only cohort of 52 were measured using a branched chain DNA assay. Spearman rank correlations of the transcripts, and histomorphological and clinical variables were determined. AR-V7 and V1 levels were assessed as determinants of recurrence in the mixed grade cohort by logistic regression and survival analysis. The impact of TMPRSS2-ERG gene fusion on prognosis was also evaluated. Results: Neither AR-V7 nor V1 levels in grade 3 or 4/5 cancer in the mixed grade cohort were associated with recurrence or time to recurrence. However, AR-V7 and V1 inversely correlated with serum prostate specific antigen and positively correlated with age. The AR-V1 level in grade 3 cancer in the grade 3 only cohort was higher than in grade 3 or grade 4/5 components of mixed grade cancer. TMPRSS2-ERG fusion was not associated with AR-V7, AR-V1 or recurrence but it was associated with the percent of grade 4/5 cancer. Conclusions: The AR-V1 or V7 transcript level does not predict recurrence in patients with high grade prostate cancer at indeterminate risk for progression. Grade 3 cancer in mixed grade tumors may differ from 100% grade 3 cancer, at least in AR-V1 expression. References 1 : Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol2011; 25: 897. Google Scholar 2 : Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res2009; 69: 16. Google Scholar 3 : A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res2009; 69: 2305. Google Scholar 4 : Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One2011; 6: e19059. Google Scholar 5 : Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A2010; 107: 16759. Google Scholar 6 : Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer2002; 95: 281. Google Scholar 7 : An updated catalog of prostate cancer predictive tools. Cancer2008; 113: 3075. Google Scholar 8 : Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst2006; 98: 715. Google Scholar 9 : Biological determinants of cancer progression in men with prostate cancer. JAMA1999; 281: 1395. Crossref, Medline, Google Scholar 10 : Identification of novel reference genes using multiplatform expression data and their validation for quantitative gene expression analysis. PLoS One2009; 4: e6162. Google Scholar 11 : Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol2010; 183: 2054. Link, Google Scholar 12 : Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol2006; 24: 3973. Google Scholar 13 : Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. J Mol Diagn2008; 10: 169. Google Scholar 14 : Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science1996; 272: 1167. Google Scholar 15 : Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol1994; 32: 2088. Google Scholar 16 : Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine1994; 12: 1503. Google Scholar 17 : Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol2010; 177: 229. Google Scholar 18 R: A language and environment for statistical computing. Team RDC. In: . Vienna, Austria: R Foundation for Statistical Computing2010: 409. Google Scholar 19 : ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis2012; 15: 165. Google Scholar 20 : ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol2011; 25: 471. Google Scholar 21 : ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res2011; 17: 5878. Google Scholar 22 : Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer2010; 102: 570. Google Scholar 23 : Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet2010; 42: 668. Google Scholar 24 : Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol2010; 41: 781. Google Scholar 25 : Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer2007; 110: 1967. Google Scholar 26 : Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest2010; 120: 2715. Google Scholar 27 : Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab2001; 86: 724. Google Scholar 28 : Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. Aging Cell2011; 10: 868. Google Scholar 29 : Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One2011; 6: e27970. Google Scholar 30 : A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate2011; 71: 1656. Google Scholar Department of Urology, Stanford University School of Medicine, Stanford, California© 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byTaneja S (2014) Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerJournal of Urology, VOL. 193, NO. 2, (538-540), Online publication date: 1-Feb-2015. Volume 188Issue 6December 2012Page: 2158-2164Supplementary Materials Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.Keywordsneoplasm recurrence, localreceptors, androgenprostatic neoplasmsprostate-specific antigenprostateMetricsAuthor Information Hongjuan Zhao More articles by this author Marc A. Coram More articles by this author Rosalie Nolley More articles by this author Stephen W. Reese More articles by this author Sarah R. Young More articles by this author Donna M. Peehl More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
- W2108709857 created "2016-06-24" @default.
- W2108709857 creator A5005340500 @default.
- W2108709857 creator A5022356999 @default.
- W2108709857 creator A5052481553 @default.
- W2108709857 creator A5076664506 @default.
- W2108709857 creator A5077592017 @default.
- W2108709857 creator A5090987054 @default.
- W2108709857 date "2012-12-01" @default.
- W2108709857 modified "2023-10-16" @default.
- W2108709857 title "Transcript Levels of Androgen Receptor Variant AR-V1 or AR-V7 Do Not Predict Recurrence in Patients with Prostate Cancer at Indeterminate Risk for Progression" @default.
- W2108709857 cites W1515728685 @default.
- W2108709857 cites W1599031322 @default.
- W2108709857 cites W1854893054 @default.
- W2108709857 cites W1968629884 @default.
- W2108709857 cites W1973368085 @default.
- W2108709857 cites W1975609403 @default.
- W2108709857 cites W1993060456 @default.
- W2108709857 cites W1996570931 @default.
- W2108709857 cites W2005302422 @default.
- W2108709857 cites W2012139740 @default.
- W2108709857 cites W2016636564 @default.
- W2108709857 cites W2030794326 @default.
- W2108709857 cites W2050517163 @default.
- W2108709857 cites W2053475946 @default.
- W2108709857 cites W2057672608 @default.
- W2108709857 cites W2075014972 @default.
- W2108709857 cites W2077038168 @default.
- W2108709857 cites W2083926838 @default.
- W2108709857 cites W2088494800 @default.
- W2108709857 cites W2097226696 @default.
- W2108709857 cites W2100001148 @default.
- W2108709857 cites W2104022977 @default.
- W2108709857 cites W2114022883 @default.
- W2108709857 cites W2130387435 @default.
- W2108709857 cites W2132693833 @default.
- W2108709857 cites W2139893960 @default.
- W2108709857 cites W2146191095 @default.
- W2108709857 cites W2149131962 @default.
- W2108709857 cites W2155987515 @default.
- W2108709857 doi "https://doi.org/10.1016/j.juro.2012.08.014" @default.
- W2108709857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23088973" @default.
- W2108709857 hasPublicationYear "2012" @default.
- W2108709857 type Work @default.
- W2108709857 sameAs 2108709857 @default.
- W2108709857 citedByCount "24" @default.
- W2108709857 countsByYear W21087098572013 @default.
- W2108709857 countsByYear W21087098572014 @default.
- W2108709857 countsByYear W21087098572015 @default.
- W2108709857 countsByYear W21087098572016 @default.
- W2108709857 countsByYear W21087098572017 @default.
- W2108709857 countsByYear W21087098572018 @default.
- W2108709857 countsByYear W21087098572019 @default.
- W2108709857 countsByYear W21087098572021 @default.
- W2108709857 countsByYear W21087098572023 @default.
- W2108709857 crossrefType "journal-article" @default.
- W2108709857 hasAuthorship W2108709857A5005340500 @default.
- W2108709857 hasAuthorship W2108709857A5022356999 @default.
- W2108709857 hasAuthorship W2108709857A5052481553 @default.
- W2108709857 hasAuthorship W2108709857A5076664506 @default.
- W2108709857 hasAuthorship W2108709857A5077592017 @default.
- W2108709857 hasAuthorship W2108709857A5090987054 @default.
- W2108709857 hasConcept C121608353 @default.
- W2108709857 hasConcept C126322002 @default.
- W2108709857 hasConcept C126894567 @default.
- W2108709857 hasConcept C143998085 @default.
- W2108709857 hasConcept C202444582 @default.
- W2108709857 hasConcept C2776235491 @default.
- W2108709857 hasConcept C2780192828 @default.
- W2108709857 hasConcept C33923547 @default.
- W2108709857 hasConcept C61367390 @default.
- W2108709857 hasConcept C71924100 @default.
- W2108709857 hasConcept C94624232 @default.
- W2108709857 hasConceptScore W2108709857C121608353 @default.
- W2108709857 hasConceptScore W2108709857C126322002 @default.
- W2108709857 hasConceptScore W2108709857C126894567 @default.
- W2108709857 hasConceptScore W2108709857C143998085 @default.
- W2108709857 hasConceptScore W2108709857C202444582 @default.
- W2108709857 hasConceptScore W2108709857C2776235491 @default.
- W2108709857 hasConceptScore W2108709857C2780192828 @default.
- W2108709857 hasConceptScore W2108709857C33923547 @default.
- W2108709857 hasConceptScore W2108709857C61367390 @default.
- W2108709857 hasConceptScore W2108709857C71924100 @default.
- W2108709857 hasConceptScore W2108709857C94624232 @default.
- W2108709857 hasIssue "6" @default.
- W2108709857 hasLocation W21087098571 @default.
- W2108709857 hasLocation W21087098572 @default.
- W2108709857 hasOpenAccess W2108709857 @default.
- W2108709857 hasPrimaryLocation W21087098571 @default.
- W2108709857 hasRelatedWork W1530301808 @default.
- W2108709857 hasRelatedWork W1980245127 @default.
- W2108709857 hasRelatedWork W1997793819 @default.
- W2108709857 hasRelatedWork W2038565121 @default.
- W2108709857 hasRelatedWork W2094328082 @default.
- W2108709857 hasRelatedWork W2127440557 @default.
- W2108709857 hasRelatedWork W2140855177 @default.
- W2108709857 hasRelatedWork W2590008096 @default.
- W2108709857 hasRelatedWork W2897445903 @default.